Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence
- PMID: 12825819
- DOI: 10.1023/a:1023935621976
Telomerase activity in pituitary adenomas: significance of telomerase expression in predicting pituitary adenoma recurrence
Abstract
Clinical and histopathological evaluations are inadequate for assessing biological aggressiveness and regrowth potential in benign pituitary adenomas. To develop reliable and prognostically informative means of predicting behavior remains an intractable problem. Telomerase, a reverse transcriptase that extends telomere length, may facilitate tumorigenesis and tumor immortality. In the present study, we investigated the telomerase activity of pituitary adenomas, and attempted to assess the value of telomerase expression for predicting their clinical course. In total, 31 (30 patients) benign pituitary adenoma samples including 8 recurrent adenomas were studied. Telomerase expression was evaluated by polymerase chain reaction (PCR)-based telomeric repeat amplification protocol (TRAP) assay and telomerase activity levels were quantitated by improved PCR enzyme-linked immunosorbent assay (ELISA). The data were analyzed in relation to clinical course which was reviewed at 4-5.5 years (median follow-up time, 52.5 months) after surgery. The relative values of the telomerase expression for predicting the clinical course were compared with the MIB-1 antigen-based proliferative cell index (PCI) and p53 immunoreactivity which have recently been suggested to correlate with aggressive behavior in pituitary adenomas. Overall, telomerase expression was detected in 13% of the adenomas (4 tumor tissues, 3 patients). These adenomas comprised large, invasive, and functioning adenomas. The number of telomerase-positive adenomas was small; however, the PCI was higher in cases with telomerase expression (4 tumor tissues; mean, 4.2 +/- 2.4%) than in those without it (27 tumor tissues; 1.4 +/- 1.3%) (p = 0.01). One tumor with detectable telomerase expression, which did not undergo additional pharmacological or radiotherapeutic intervention after first surgery, recurred rapidly despite gross total surgical resection, although the PCI of both the primary and recurrent adenomas was not high. Detection of telomerase expression may represent an additional useful means of identifying aggressive behavior, complementing the histopathological evaluation of benign-appearing pituitary adenomas.
Similar articles
-
[Significance of p53 protein expression and proliferative potential with MIB-1 on tumor recurrence of pituitary adenomas].No To Shinkei. 1998 Jan;50(1):27-32. No To Shinkei. 1998. PMID: 9493195 Japanese.
-
Telomerase activity and the expression of telomerase components in pituitary adenoma with malignant transformation.Surg Neurol. 2000 Mar;53(3):267-74. doi: 10.1016/s0090-3019(00)00181-6. Surg Neurol. 2000. PMID: 10773260
-
Pituitary tumour transforming gene (PTTG) expression correlates with the proliferative activity and recurrence status of pituitary adenomas: a clinical and immunohistochemical study.Clin Endocrinol (Oxf). 2006 Oct;65(4):536-43. doi: 10.1111/j.1365-2265.2006.02630.x. Clin Endocrinol (Oxf). 2006. PMID: 16984249
-
Labeling index in pituitary adenomas evaluated by means of MIB-1: is there a prognostic role? A critical review.Neurol Res. 2010 Dec;32(10):1060-71. doi: 10.1179/016164110X12670144737855. Epub 2010 May 18. Neurol Res. 2010. PMID: 20483025 Review.
-
Aggressive pituitary tumors.Oncology (Williston Park). 1998 Sep;12(9):1307-12, 1315; discussion 1315-8. Oncology (Williston Park). 1998. PMID: 9778677 Review.
Cited by
-
Study of the telomerase hTERT fraction, PCNA and CD34 expression on pituitary adenomas. Association with clinical and demographic characteristics.J Neurooncol. 2007 Sep;84(2):159-66. doi: 10.1007/s11060-007-9365-8. Epub 2007 Mar 15. J Neurooncol. 2007. PMID: 17361328
-
The hallmarks of cancer… in pituitary tumors?Rev Endocr Metab Disord. 2023 Apr;24(2):177-190. doi: 10.1007/s11154-022-09777-y. Epub 2022 Dec 31. Rev Endocr Metab Disord. 2023. PMID: 36586070 Review.
-
Prognostic indicators in pituitary tumors.Endocr Pathol. 2005 Spring;16(1):1-9. doi: 10.1385/ep:16:1:001. Endocr Pathol. 2005. PMID: 16000840 Review.
-
Telomerase detection in the diagnosis and prognosis of cancer.Cytotechnology. 2004 Jun;45(1-2):61-74. doi: 10.1007/s10616-004-5126-0. Cytotechnology. 2004. PMID: 19003244 Free PMC article.
-
My approach to pathology of the pituitary gland.J Clin Pathol. 2006 Dec;59(12):1245-53. doi: 10.1136/jcp.2005.031187. J Clin Pathol. 2006. PMID: 17142570 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous